2. Insulin inhaler from Aerogen and Dance Pharmaceuticals

Aerogen and Dance Pharmaceuticals are confident they can succeed where Pfizer's ($PFE) Exubera and others failed, planning to market an inhalable insulin platform. Ireland's Aerogen is a maker of aerosol-based delivery platforms, and the San Francisco-based Dance develops inhaled insulins, so the partnership was natural. And why do the two companies think they won't find themselves in the same boat as Pfizer? Exubera's flop was due, in large part, to its unwieldy delivery platform--the inhaler was the size of a Pringles can--and it certainly didn't help that the product was deemed prohibitively expensive by payers and regulators. Aerogen and Dance, however, are working with the former's wafer-thin QnQ aerosol generator, a dome-shaped aperture plate that uses vibration to pump low-velocity aerosol deep into the lungs. They plan to pair that tech with Dance's inhalable insulin and package the whole thing in a pocket-sized device, providing painless, non-invasive treatment for diabetics. The two firms are targeting 2016 for regulatory approval.

2. Insulin inhaler from Aerogen and Dance Pharmaceuticals

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.